Pelthos Therapeutics Inc. (PTHS) is a publicly traded Healthcare sector company. As of May 21, 2026, PTHS trades at $27.45 with a market cap of $90.89M and a P/E ratio of -1.16. PTHS moved -0.52% today. Year to date, PTHS is -12.55%; over the trailing twelve months it is flat. Its 52-week range spans $13.76 to $54.29. Analyst consensus is strong buy with an average price target of $57.71. Rallies surfaces PTHS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for PTHS, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $27.45 |
| Market Cap | $90.89M |
| P/E Ratio | -1.16 |
| EPS | $-23.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $54.29 |
| 52-Week Low | $13.76 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $16.80M |
| Net Income | $-43.32M |
| Gross Margin | 76.25% |
7 analysts cover PTHS: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $57.71.